Protein disulphide isomerase-mediated LA419– NO release provides additional antithrombotic effects to the blockade of the ADP receptor

Summary

Despite the proven efficacy of current antithrombotic therapy in preventing ischemic heart disease (IHD), vascular events still occur. Our aims were i) to evaluate if combined oral treatment of clopidogrel and LA419, a novel nitric oxide donor with antiischemic and antiplatelet properties, provides additional antiplatelet effects to those of the blockade of P2Y₁₂ receptor; and ii) to gain insight into the mechanism behind LA419 antiplatelet effects. Pigs (n=16) were randomized into four groups: 1) placebocontrol; 2) LA419; 3) clopidogrel; and 4) LA419+clopidogrel. Both compounds were administered orally: LA419 0.9 mg kg^-1 twice daily for 10 days; clopidogrel 10 mg kg^-1 day the three last days. Antithrombotic effects were assessed by measuring platelet deposition (PD) triggered by denuded and disrupted vessel wall placed on the Badimon chamber. LA419 effects on platelet aggregation, hemodynamic parameters, and platelet protein expression upon in vitro thrombin stimulation were also evaluated. Total PD on denuded vessels was similarly reduced by all treatments with respect to placebo (p<0.05). However, combination of LA419+clopidogrel largely reduced PD triggered by disrupted vessel wall by 80% versus placebo (p<0.005), 15% versus clopidogrel alone (p<0.01), and 30% versus LA419 alone (p<0.005). All treatments inhibited collagen- and ADP-induced platelet aggregation, and no variations were detected in hemodynamic parameters. Proteomic analysis revealed that LA419 was associated with an increase in membrane protein disulphide isomerase (protein implicated in nitric oxide release).Treatment with LA419 may result in additional antiplatelet effect to that of clopidogrel in addition to restoring impaired endothelial dependent vasodilation without hemodynamic side effects. Further studies in IHD patients seem warranted.

Keywords

Thrombosis - platelets - nitric - oxide

• References

• 1 Harrington RA, Becker RC, Ezekowitz M. et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 513S-548S.
• 2 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
• 3 Hollopeter G, Jantzen HM, Vincent D. et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
• 4 Curtin R, Cox D, Fitzgerald D. Clopidogrel and ticlopidine. Michelson AD, editor. Platelets. Amsterdam: Academic Press; 2002: 787-801.
• 5 Main C, Palmer S, Griffin S. et al. Clopidogrel usedin combinationwith aspirin compared withaspirinalone in thetreatment of non-ST-segment-elevationacute coronary syndromes: asystematic review andeconomicevaluation. HealthTechnol Assess 2004; 8: 1-141. iii-iv, xv-xvi
• 6 Gibbons RJ, Abrams J, Chatterjee K. et al. ACC/ AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003; 41: 159-168.
• 7 Macchi L, Christiaens L, Brabant S. et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107: 45-49.
• 8 Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45: 1157-1164.
• 9 Serebruany VL, Steinhubl SR, Berger PB. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
• 10 Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med 1998; 338: 520-531.
• 11 International patent number WO 00/20420. Intellectual property world organization. Derivatives of isosorbid mononitrate as vasodilator agents with reduced tolerance.
• 12 Vilahur G, Segales E, Casani L. et al. A novel antiischemic nitric oxide donor inhibits thrombosis without modifying haemodynamic parameters. Thromb Haemost 2004; 91: 1035-1043.
• 13 Maree AO, Cox D. Thrombosis and nitric oxide donor drugs. Thromb Haemost 2004; 91: 848-850.
• 14 Badimon L, Turitto V, Rosemark JA. et al. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J Lab Clin Med 1987; 110: 706-718.
• 15 Vilahur G, Segales E, Salas E. et al. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flowand lesion-dependent thrombosis in the porcine ex vivo model. Circulation 2004; 110: 1686-1693.
• 16 Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 1989; 84: 1134-1144.
• 17 Badimon L, Badimon JJ, Galvez A. et al. Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. Arteriosclerosis 1986; 6: 312-320.
• 18 Makkar RR, Eigler NL, Kaul S. et al. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J 1998; 19: 1538-1546.
• 19 Jeremias A, Sylvia B, Bridges J. et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109: 1930-1932.
• 20 Galvez A, Badimon L, Badimon JJ. et al. Electrical aggregometry in whole blood from human, pig and rabbit. Thromb Haemost 1986; 56: 128-132.
• 21 Molloy M, Herbert B, Walsh B. et al. Extraction of membrane proteins by differential solubilization for separation using two-dimensional gel electrophoresis. Electrophoresis 1998; 19: 837-844.
• 22 Llorente-Cortes V, Martinez-Gonzalez J, Badimon L. Esterified cholesterol accumulation induced by ag- gregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. Arterioscler Thromb Vasc Biol 1998; 18: 738-746.
• 23 Mason PJ, Freedman JE, Jacobs AK. Aspirin resistance: current concepts. Rev Cardiovasc Med 2004; 5: 156-163.
• 24 Kaul S, Naqvi TZ, Fishbein MC. et al. Local delivery of an ultra-short-acting nitric oxide-releasing compound, DMHD/NO, is highly effective in inhibiting acute platelet-thrombus formation on injured arterial strips. J Cardiovasc Pharmacol Ther 1997; 2: 181-194.
• 25 Tomasiak M SH, Rusak T, Wysocka J. Nitric oxide and platelet energy metabolism. Acta Biochim Pol 2004; 51: 789-803.
• 26 Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61: 498-511.
• 27 Danielewski O, Schultess J, Smolenski A. The NO/ cGMP pathway inhibits Rap 1 activation in human platelets via cGMP-dependent protein kinase I. Thromb Haemost 2005; 93: 319-325.
• 28 Schafer A, Wiesmann F, Neubauer S. et al. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 2004; 109: 1819-1822.
• 29 Massberg S, Gruner S, Konrad I. et al. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood 2004; 103: 136-142.
• 30 Eigenthaler M, Nolte C, Halbruegge M. et al. Concentration and regulation of cyclic nucleotides, cyclicnucleotide- dependent protein kinases and one of their major substrates in human platelets: estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur J Biochem 1992; 205: 471-481.
• 31 Aszódi A, Pfeifer A, Ahmad M. et al. The vasodilator- stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J 1999; 18: 37-48.
• 32 Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993; 329: 2002-2012.
• 33 Keh D, Thieme A, Kurer I. et al. Inactivation of platelet glycoprotein IIb/IIIa receptor by nitric oxide donor 3-morpholino-sydnonimine. Blood Coagul Fibrinolysis 2003; 14: 327-334.
• 34 Roald HE, Barstad RM, Kierulf P. et al. Clopidogrel-- a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost 1994; 71: 655-662.
• 35 Steele PM, Chesebro JH, Stanson AW. et al. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985; 57: 105-112.
• 36 Lam JY, Chesebro JH, Fuster V. Platelets, vasoconstriction, and nitroglycerin during arterial wall injury. A new antithrombotic role for an old drug. Circulation 1988; 78: 712-716.
• 37 Essex DW, Chen K, Swiatkowska M. Localization of protein disulfide isomerase to the external surface of the platelet plasma membrane. Blood 1995; 86: 2168-2173.
• 38 Lahav J, Wijnen EM, Hess O. et al. Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin alpha2beta1. Blood 2003; 102: 2085-2092.
• 39 Garcia Moll M. Principles and rules of the use of nitrates. Ann Cardiol Angeiol (Paris) 1997; 46: 399-405.
• 40 von Beckerath N, Taubert D, Pogatsa-Murray G. et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005; 112: 2946-2950.
• 41 Wiviott SD, Antman EM, Winters KJ. et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111: 3366-3373.